linjc16/ctgov huggingface dataset:
Serum Ghrelin in Polycystic Ovary Syndrome

Study Overview
=================
Brief Summary
-----------------
measuring serum gherlin in polycystic ovary syndrome patients and compare it to healthy levels

Detailed Description
-----------------
two groups one healthy and other with pco measure ghrelin level in both of them to find relation between pco and ghrelin

Official Title
-----------------
Ghrelin in Polycystic Ovary Syndrome

Conditions
-----------------
Polycystic Ovary

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:pco women At least 12 months of infertility. Patients with polycystic ovarian syndrome according to Rotterdam criteria: Exclusion Criteria: Patients with hyperprolactinemia Patients with Cushing's syndrome Patients with Congenital or non-classical adrenal hyperplasia Patients with hormone secreting tumors. Patients with hormonal treatment in the last 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| study<br>patients with polycystic ovary syndrome | |
| control<br>healthy patients serves as control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| relationships between circulating ghrelin and the clinical and biochemical manifestations of PCOS | Analysis of levels of ghrelin in study group | after 6 monthes |
Can Malnutrition be Prevented in Patient With Colorectal Cancer Stage Dukes D?

Study Overview
=================
Brief Summary
-----------------
The purpose of this randomised intervention study is to investigate to what degree patients with colorectal cancer benefit of dietary counselling regarding nutritional status, oncologic treatment and quality of life.

Official Title
-----------------
A Randomised Study of Dietary Counseling for Patients With Colorectal Cancer.

Conditions
-----------------
Colorectal Neoplasm

Intervention / Treatment
-----------------
* Other: Individual dietary counseling.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: metastatic colorectal cancer histological verified cancer age >18 years Exclusion Criteria: cognitive reduction confusion not able to answer questionaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Dietary counseling<br>Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary. | Other: Individual dietary counseling.<br>* Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.<br>* Other names: Dietary intervention.;|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight |  | 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body composition |  | 2 year | 
| Quality of life |  | 2 years | 
| Oncologic treatment |  | 2 years | 
| Dietary intake |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dietary intake, Dietary counseling, Weight loss, Body composition, Resting energy expenditure, Quality of life
Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer

Study Overview
=================
Brief Summary
-----------------
We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.

Official Title
-----------------
A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors

Conditions
-----------------
Locally Advanced Stage III or IV Thymic Cancer

Intervention / Treatment
-----------------
* Drug: neoadjuvant docetaxel/cisplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically confirmed thymic carcinoma surgically inoperable Masaoka stage III or IV ECOG 0-2 at least one measurable disease Exclusion Criteria: previous myocardiac infarct history within 1 year before the enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: neoadjuvant chemotherapy<br>3 cycles of docetaxel/cisplatin before operation | Drug: neoadjuvant docetaxel/cisplatin<br>* 3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete resection rate |  | 4-8 weeks later after completion of neoadjuvant chemotherapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of patients with adverse events |  | from enrollment to 6 months after completion of chemotherapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neoadjuvant chemotherapy, thymic cancer
STEMI Versus NSTEMI: Clinical and Angiographic Differences

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess differences in the risk profile and in the coronary angiographic presentation between STEMI and NSTEMI. Moreover possible relationship between myocardial infarction presentation and renal function will be investigated.

Detailed Description
-----------------
Assessment of risk profile. Diabetes mellitus diagnosed when fasting blood glucose (FBG) was >= 126mg/dL or if patients were taking oral hypoglycaemic drugs or were on insulin treatment. Hypertension defined as blood pressure >= 140/90 mmHg or history of antihypertensive treatment. Hypercholesterolemia,adjudicated when cholesterol levels were >= 200 mg/dL or with patients on lipid lowering treatment. Hypertriglyceridemia adjudicated on fasting triglyceride levels>= 200 mg/dL or triglyceride-lowering therapy . Obesity, defined as BMI >= 30 kg/m2. Patients with STEMI, who had not been previously treated with thrombolysis, and those who had been undergone to an unsuccessful thrombolysis, as well as patients with NSTEMI with a TIMI score> 3 who were immediately referred to the Cat Lab and whenever possible treated with PTCA and stenting of the culprit lesion. The other patients who were referred to Cat Lab within 48 hours from the beginning of chest pain, unless their general conditions did not strongly suggest to delay the procedure after 2 more days.

Official Title
-----------------
STEMI Versus NSTEMI: a Mono Versus a Multivessel Disease?

Conditions
-----------------
Acute Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted in the coronary care unit (CCU) of the Department of Clinical and Experimental Medicine at the Federico 2nd University Hospital; Patient with indication to angiographic study even if not immediately; Patients referred to CCU with the diagnosis of acute myocardial infraction (AMI), type STEMI, or NSTEMI, based on pre-admission assessment of troponin I (TpI) and myocardial band creatin kinase (CK-MB; Diagnosis of NSTEMI/STEMI performed according to standard criteria Exclusion criteria: Patients who could not undergo angiographic study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
myocardial infarction, coronary angiography, STEMI, NSTEMI
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses. This study will use a medical imaging technique called Positron Emission Tomography (PET) which uses an imaging agent called [11C]-WAY100635.

Official Title
-----------------
An Open Label, Non-randomized Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain 5-HT1A Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK163090, Using the Ligand [11C]-WAY100635.

Conditions
-----------------
Healthy Subjects, Depressive Disorder and Anxiety Disorders

Intervention / Treatment
-----------------
* Drug: GSK163090


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male subjects, aged 18-45 years Body weight > 50 kg Non-Smoker Normal ECG, heart rate and blood pressure Exclusion Criteria: History of any cardiac disease History of regular alcohol consumption averaging >14 drinks/week Current or recent gastrointestinal disease; History of psychiatric illness including any history of suicidal attempts Positive for Hepatitis B and C, and HIV. History of drug abuse. Exposure to research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden Family history of cancer (one or more first-degree relative diagnosed before the age of 55). Suffers from claustrophobia History or presence of neurological or psychiatric conditions Presence of a cardiac pacemaker or other implanted electronic device or metal implants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: GSK163090<br>one infusion only | Drug: GSK163090<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain receptor occupancy of GSK163090 Plasma concentrations of GSK163090 |  | throughout the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitals signs ECGs Clinical Laboratory test results |  | throughout the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PET scan, healthy males
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire

Official Title
-----------------
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of informed consent Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment. Exclusion Criteria: Allergy to substance of medication Pre-perimenopausal woman Woman not eligible for treatment
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Elements of the investigator questionnaire SF RAND-36 questionnaire |  | Quarterly (plus or minus 3 days ) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Investigator Assessment Report |  | Yearly (plus or minus 1 week ) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of Life
Platelet Activation Markers in Pediatric Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
In this study the focus will be on correlating the levels of platelet activation markers (proteins that are released when blood cells are activated)to the duration of cardiopulmonary bypass, temperature during cardiopulmonary bypass and the weight of the patient.

Detailed Description
-----------------
This research is being done because we would like to learn more about platelet dysfunction in children undergoing cardiopulmonary bypass. It has been an established fact that cardiopulmonary bypass causes dysfunction in platelets. Activation of platelets during cardiopulmonary bypass is implicated as being a major factor in causing platelet dysfunction. For all participants, approximately 3.15 ml of blood will be collected in special tubes called CTAD tubes, before and after cardiopulmonary bypass (6.30ml in total). This amount of blood draw is well within the guidelines of NIH (National Institute of Health). Enzyme-linked immunosorbent assay (ELISA) will be performed using this plasma to make quantitative assessment of Platelet factor 4 and Transforming growth factor beta.

Official Title
-----------------
Effect of Cardiopulmonary Bypass on Platelet Activation Markers Such as Platelet Factor 4 and Transforming Growth Factor B, in Pediatric Cardiac Surgery

Conditions
-----------------
Coronary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled to have surgery involving cardiopulmonary bypass for congenital cardiac abnormalities. Age: Newborn to 7 years Gender: male and female Exclusion Criteria: Emergency surgery Weight less than 3 kg Age greater than 7 years Patients with low platelet counts (<100,000) Patients on medications that are known to interfere with platelet function such as prostacyclins, non-steroidal anti-inflammatory drugs, plavix. Patients whose parents not willing to give consent

Ages Eligible for Study
-----------------
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric, Cardiopulmonary bypass Surgery, Cardiac Surgery, Platelet, Platelet Activation Markers, Platelet Factor4, Transforming Growth Factor Beta
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.

Detailed Description
-----------------
Choosing to participate in an early patient access program is an important personal decision. Talk with your doctor and family members or friends about deciding to participate in an early patient access program. To learn more about early patient access programs, your doctor may contact BMS using the information provided below.

Official Title
-----------------
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Biological: Elotuzumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Specific eligibility criteria must be met for access outside of a clinical trial. These inclusion criteria include: The illness must be serious or life threatening There are no other viable options (including approved products or active clinical trials) There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time Other defined inclusion/exclusion criteria could be applicable.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Clinical Outcomes of the Implementation of Diurnal IOP Curve to 1500 Patients - A Cohort Study.

Study Overview
=================
Brief Summary
-----------------
To present the clinical outcomes of diurnal IOP monitoring and determine its value in our clinical practice.We reviewed the records of 1500 patients (glaucoma suspects or glaucoma patients), who were admitted for diurnal curve during almost 12 years.

Detailed Description
-----------------
We reviewed the records of 1500 patients, who were admitted for diurnal curve during almost 12 years. All patients were hospitalized because their within office-hours exams were considered inadequate and inconclusive for decision-making 744 patients needed change of treatment. 121 patients were programmed for interventional therapy (laser or surgery). 68 patients were declassified, as overdiagnosed and overtreated. In 250 patients hidden adherence problem revealed. In 720 patients peak IOP occurred out of office hours.

Official Title
-----------------
Clinical Outcomes of the Implementation of Diurnal IOP Curve to 1500 Patients - A Cohort Study.

Conditions
-----------------
To Present the Clinical Outcomes of Diurnal IOP Monitoring and Determine Its Value in Our Clinical Practice

Intervention / Treatment
-----------------
* Other: IOP monitoring data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IOP diurnal curve consisted of glaucoma patients with intraocular pressure higher than target pressure despite referred previously sufficient therapy and also patients with equal or lower than target pressure, but with disease progression. There were also included patients with advanced glaucoma with visual field defects on the visual field testing, as well as patients with normal tension glaucoma and labile secondary glaucomas (exfoliative, pigmentary and chronic angle closure glaucoma), for whom close monitoring and therapy reconsidering was judged appropriate.Glaucoma suspects, demonstrating findings consistent with increased risk for glaucoma development, were included. - Exclusion Criteria: Patients with missing data values for IOP -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: IOP monitoring data|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diurnal IOP monitoring | This analysis provides a real life' account of IOP in a large number of glaucoma suspects and patients. Our results demonstrate the potential for significant additional information, being obtained from diurnal IOP monitoring, in clinical practice. | 12 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tonometric curve, diurnal IOP, IOP phasing, IOP monitoring, glaucoma, glaucoma suspects, IOP peaks, hypertension, compliance, adherence,